Rolafagrel

罗拉格雷

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRolafagrel
Drug Alias NameFCE-22178
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThromboxane A2 synthase inhibitors
TargetsThromboxane A2 synthase
Therapy Area/IndicationsThrombosisDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsThrombosisDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A